Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Krystal Biotech Ramps Up to Manufacture Gene Therapy to Treat Dystrophic Epidermolysis Bullosa
Krystal Biotech Ramps Up to Manufacture Gene Therapy to Treat Dystrophic Epidermolysis Bullosa
Krystal Biotech Ramps Up to Manufacture Gene Therapy to Treat Dystrophic Epidermolysis Bullosa
Submitted by
admin
on January 15, 2019 - 9:59am
Source:
CP Wire
News Tags:
Krystal Biotech
KB103
dystrophic epidermolysis bullosa
Headline:
Krystal Biotech Ramps Up to Manufacture Gene Therapy to Treat Dystrophic Epidermolysis Bullosa
snippet:
Facility will officially open in 1Q 2019
Ph I/II study on KB103 interim results met primary and secondary endpoints
Do Not Allow Advertisers to Use My Personal information
